The Oncolytic Caprine Herpesvirus 1 (CpHV-1) Induces Apoptosis and Synergizes with Cisplatin in Mesothelioma Cell Lines: A New Potential Virotherapy Approach.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
08 12 2021
Historique:
received: 22 09 2021
revised: 12 11 2021
accepted: 03 12 2021
entrez: 28 12 2021
pubmed: 29 12 2021
medline: 15 2 2022
Statut: epublish

Résumé

Malignant mesothelioma (MM) is an aggressive asbestos-related cancer, against which no curative modalities exist. Oncolytic virotherapy is a promising therapeutic approach, for which MM is an ideal candidate; indeed, the pleural location provides direct access for the intra-tumoral injection of oncolytic viruses (OVs). Some non-human OVs offer advantages over human OVs, including the non-pathogenicity in humans and the absence of pre-existing immunity. We previously showed that caprine herpesvirus 1 (CpHV-1), a non-pathogenic virus for humans, can kill different human cancer cell lines. Here, we assessed CpHV-1 effects on MM (NCI-H28, MSTO, NCI-H2052) and non-tumor mesothelial (MET-5A) cells. We found that CpHV-1 reduced cell viability and clonogenic potential in all MM cell lines without affecting non-tumor cells, in which, indeed, we did not detect intracellular viral DNA after treatment. In particular, CpHV-1 induced MM cell apoptosis and accumulation in G0/G1 or S cell cycle phases. Moreover, CpHV-1 strongly synergized with cisplatin, the drug currently used in MM chemotherapy, and this agent combination did not affect normal mesothelial cells. Although further studies are required to elucidate the mechanisms underlying the selective CpHV-1 action on MM cells, our data suggest that the CpHV-1-cisplatin combination could be a feasible strategy against MM.

Identifiants

pubmed: 34960727
pii: v13122458
doi: 10.3390/v13122458
pmc: PMC8703924
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Cancer Res. 2008 Jun 15;68(12):4882-92
pubmed: 18559536
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664483
Oncoimmunology. 2015 Dec 8;5(1):e1115641
pubmed: 26942095
Oncolytic Virother. 2015 Sep 10;4:133-40
pubmed: 27512676
Cell Cycle. 2014;13(4):652-65
pubmed: 24345738
Science. 1990 Nov 30;250(4985):1262-6
pubmed: 2173860
J Thorac Dis. 2013 Dec;5(6):E254-307
pubmed: 24416529
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848954
Vet Immunol Immunopathol. 2005 Feb 10;103(3-4):283-93
pubmed: 15621313
Exp Biol Med (Maywood). 2019 Sep;244(12):983-991
pubmed: 31299861
Front Cell Infect Microbiol. 2018 Nov 19;8:396
pubmed: 30510918
Lancet Oncol. 2021 Feb;22(2):190-197
pubmed: 33450184
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
Front Oncol. 2017 Aug 24;7:179
pubmed: 28884088
Front Immunol. 2017 May 15;8:555
pubmed: 28555136
Semin Cancer Biol. 2020 Apr;61:11-22
pubmed: 31546009
Ann Transl Med. 2017 Jun;5(11):238
pubmed: 28706906
Drug Deliv. 2018 Nov;25(1):1950-1962
pubmed: 30799657
Cancers (Basel). 2020 Nov 28;12(12):
pubmed: 33260685
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S28-S38
pubmed: 32206568
Hum Cell. 2002 Sep;15(3):151-9
pubmed: 12703545
J Adv Res. 2015 May;6(3):319-30
pubmed: 26257929
Microb Pathog. 2019 Nov;136:103663
pubmed: 31404631
Oncotarget. 2017 May 31;8(60):102617-102639
pubmed: 29254276
Biochem Pharmacol. 2020 Jul;177:113986
pubmed: 32330494
Oncoimmunology. 2019 Mar 28;8(6):e1581528
pubmed: 31069150
Viruses. 2019 Jun 18;11(6):
pubmed: 31216641
J Virol. 1999 Oct;73(10):8245-55
pubmed: 10482575
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
J Thorac Oncol. 2016 Feb;11(2):142-54
pubmed: 26811225
Int J Mol Sci. 2020 Nov 05;21(21):
pubmed: 33167582
Pathogens. 2016 Feb 06;5(1):
pubmed: 26861403
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Nat Rev Cancer. 2005 Dec;5(12):965-76
pubmed: 16294217
Cancer Biol Ther. 2006 Jan;5(1):48-53
pubmed: 16294031
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Int J Mol Sci. 2020 Oct 04;21(19):
pubmed: 33020398
J Gen Virol. 1998 Aug;79 ( Pt 8):1983-7
pubmed: 9714247
Schweiz Arch Tierheilkd. 1979;121(12):655-62
pubmed: 231824
Cancer Gene Ther. 2006 Nov;13(11):975-92
pubmed: 16604059
Cancer Gene Ther. 2010 May;17(5):344-55
pubmed: 19893594
Front Oncol. 2020 Jan 24;9:1519
pubmed: 32039010
J Thorac Oncol. 2020 Jan;15(1):29-49
pubmed: 31546041
Hum Gene Ther. 2010 Jan;21(1):51-64
pubmed: 19715403
Cell. 1999 Dec 23;99(7):817-27
pubmed: 10619434
Sci Rep. 2017 Aug 23;7(1):9176
pubmed: 28835716
Front Oncol. 2019 Jul 12;9:564
pubmed: 31355131
Cancer Biol Ther. 2019;20(1):42-51
pubmed: 30409104
Cancer Gene Ther. 2002 Dec;9(12):1062-7
pubmed: 12522445
Lancet Oncol. 2018 Mar;19(3):e161-e172
pubmed: 29508763
Lancet Oncol. 2017 Sep;18(9):e532-e542
pubmed: 28884702
J Biol Chem. 2003 Jul 11;278(28):25964-9
pubmed: 12724329
J Gene Med. 2010 Aug;12(8):681-92
pubmed: 20635326
Lancet. 2005 Jul 30-Aug 5;366(9483):397-408
pubmed: 16054941
Nat Med. 2001 Jul;7(7):781-7
pubmed: 11433341

Auteurs

Iris Maria Forte (IM)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.

Paola Indovina (P)

Institute for High Performance Computing and Networking, National Research Council of Italy (ICAR-CNR), 80131 Naples, Italy.
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

Serena Montagnaro (S)

Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.

Aurora Costa (A)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Carmelina Antonella Iannuzzi (CA)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.

Francesca Capone (F)

Experimental Pharmacology Unit-Laboratories of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura deiTumori "Fondazione G. Pascale", 80131 Naples, Italy.

Rosa Camerlingo (R)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.

Anna Maria Malfitano (AM)

Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.

Francesca Pentimalli (F)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Naples, Italy.

Gianmarco Ferrara (G)

Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.

Massimiliamo Quintiliani (M)

Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Giuseppe Portella (G)

Dipartimento Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.

Antonio Giordano (A)

Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Roberto Ciarcia (R)

Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", 80137 Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH